Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
James F HowardChafic KaramMarcus YountzFanny L O'BrienTahseen Mozaffarnull nullPublished in: Annals of clinical and translational neurology (2021)
The findings suggest that, although most patients with refractory gMG will achieve clinical response by Week 12 of eculizumab treatment, first responses can be observed with longer-term treatment.
Keyphrases